Naltrexone Treatment Centers in Wyoming

Yes — a history of relapse does not disqualify you from naltrexone. In fact, repeated relapses are a strong clinical reason to start MAT, because continued use without medication carries a much higher overdose risk. Wyoming programs routinely admit patients with complex relapse histories.

Most Wyoming programs include routine urine drug screens in the program fee. Baseline lab work (liver function, pregnancy test, ECG for methadone) may be billed separately — $30–$150 depending on insurance status. Ask about lab fees at intake.

Yes. Wyoming Medicaid covers Sublocade and Vivitrol as part of the MAT benefit; most plans require prior authorization documenting prior MAT adherence. Billing is handled by the Wyoming provider as a medical (not pharmacy) benefit.

Yes — federal parity rules require employer plans to cover MAT. High-deductible plans charge patient-paid rates until the deductible is met; HSA funds can be used for MAT and medication costs. Many employers also offer EAP programs that pay for an initial assessment.

Yes. Wyoming hospitals routinely start buprenorphine in the ED and bridge patients to outpatient MAT. The state’s opioid-response plan funds ED warm-handoff coordinators who connect patients to naltrexone providers in their home zip code before discharge.

Yes. Meta-analyses consistently find that patients who remain on MAT longer than 12 months have lower rates of relapse, infectious disease, and overdose death. Wyoming Medicaid-funded programs report improved retention with long-acting injectables compared to sublingual treatment.

For methadone and buprenorphine, continued opioid use at entry is expected — the medication is designed to stop use safely. For naltrexone, 7–14 opioid-free days are required first. Your Wyoming clinician will confirm the correct induction strategy at intake.

Expect 2–3 hours for intake, medical exam, counseling assessment, and first dose or prescription. Some Wyoming clinics break intake over two visits if labs or records need to be obtained first. Plan accordingly and arrange transportation home.

Common side effects are usually mild and transient: nausea, constipation, headache, drowsiness, sweating, and insomnia. Most resolve within 1–2 weeks of dose stabilization. Persistent side effects are addressed by dose adjustment or switching medications at your Wyoming clinic.

Yes. Postpartum continuation of MAT is strongly recommended — overdose risk is elevated in the postpartum period. Wyoming programs increasingly embed MAT within postpartum home-visiting programs to support the mother-infant dyad during the first year.

Federal rules require all SAMHSA-certified OTPs to offer counseling alongside methadone. Buprenorphine and naltrexone prescribing does not mandate counseling, but Wyoming providers strongly recommend it. Most insurance plans and Wyoming Medicaid cover integrated counseling as part of the MAT benefit.

Yes. Group members sign confidentiality agreements, and the clinician protects group content under 42 CFR Part 2. Enforcement between group members depends on honor among peers, but legal protections limit disclosure by the clinic or clinician.